Antibacterial activity of lidocaine in mixtures with Diprivan

British Journal of Anaesthesia

Volumn 81, Issue 3, 1998, Pages 444-448

  Gajraj, R J ^a   Hodson, M J ^b   Gillespie, J A ^c   Kenny, G N C ^d   Scott, N B ^e  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c VICTORIA INFIRMARY   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e HCI International Medical Centre   (United Kingdom)

Author keywords

Anaesthetics i.v, propofol; Anaesthetics local, lidocaine; Formulations, concentration; Formulations, propofol; Infection, bacterial

Indexed keywords

LIDOCAINE; PROPOFOL;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM COLONY; DRUG CONTAMINATION; PRIORITY JOURNAL; SEPSIS;

EID: 0031670571     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/81.3.444     Document Type: Article

References (42)

1. Arduino MJ, Bland LA, McAllister SK, Aguero SM, Villarino ME, McNeil MM, Jarvis WR, Favero MS. Microbial growth and endotoxin production in the intravenous anesthetic propofol. Infection Control and Hospital Epidemiology 1991; 12: 535-539.
2. Tessler M, Dascal A, Giosefnni S, Miller M, Mendelson J. Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media. Canadian Journal of Anaesthesia 1992; 39: 509-511.
3. Berry CB, Gillespie T, Hood J, Scott NB. Growth of microorganisms in solutions of intravenous anaesthetic agents. Anaesthesia 1993; 48: 30-32.
4. Highsmith AK, Greenhood GP, Alien JR. Growth of nosocomial pathogens in multiple-dose parenteral medication vials. Journal of Clinical Microbiology 1982; 15: 1024-1028.
5. Sosis MB, Braverman B, Growth of Staphylococcus aureus in four intravenous anesthetics. Anesthesia and Analgesia 1993; 77: 766-768.
6. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent - California, Illinois, Maine, and Michigan, 1990. MMWR - Morbidity and Mortality Weekly Report 1990; 39: 426-433.
7. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, Burwen DR, Welbel SF, Pegues DA, Stroud L, Zeitz PS, Jarvis WR. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. New England Journal of Medicine 1995; 333: 147-154.
8. Veber B, Gachot B, Bedos JP, Wolff M. Severe sepsis after intravenous injection of contaminated propofol. Anesthesiohgy 1994; 80: 712-713.
9. Hynynen M, Korttila K, Tammisto T. Pain on i.v. injection of propofol (ICI 35 868) in emulsion formulation. Acta Anaesthesiologica Scandinavica 1985; 29: 651-652.
10. Skues MA, Prys-Roberts C. The pharmacology of propofol. Journal of Clinical Anesthesia 1989; 1: 387-400.
11. Ohsuka S, Ohta M, Masuda K, Arakawa Y, Kaneda T, Kato N. Lidocaine hydrochloride and acetylsalicylate kill bacteria by disrupting the bacterial membrane potential in different ways. Microbiology and Immunology 1994; 38: 429-434.
12. Jonnesco T. Remarks on general spinal analgesia. British Medical Journal 1909; 2: 1396-1401.
13. Erlich H. Bacteriologic studies and effects of anesthetic solutions on bronchial secretions during bronchoscopy. American Review of Respiratory Diseases 1961; 84: 414-421.
14. Silva MT, Sousa JC, Polonia JJ, Macedo PM. Effects of local anesthetics on bacterial cells. Journal of Bacteriology 1979; 137: 461-468.
15. Fazly Bazaz BS, Salt WG. Local anaesthetics as antimicrobial agents: structure-action considerations. Microbios 1983; 37: 45-64.
16. Thompson KD, Welykyj S, Massa MC. Antibacterial activity of lidocaine in combination with a bicarbonate buffer. Journal of Dermatologic Surgery and Oncology 1993; 19: 216-220.
17. Wolfson JS, Swartz MN. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. New England Journal of Medicine 1985; 312: 968-975.
18. White IW, Gelb AW, Wexler HR, Stiller CR, Keown PA. The effects of intravenous anaesthetic agents on human neutrophil chemiluminescence. Canadian Anaesthetists Society Journal 1983; 30: 506-511.
19. Bardosi L, Tekeres M. Impaired metabolic activity of phagocytic cells after anaesthesia and surgery. British Journal of Anaesthesia 1985; 57: 520-523.
20. Madsbad S, Buschard K, Siemssen O, Ropke C. Changes in T-lymphocyte subsets after elective surgery. Acta Chirurgica Scandinavica 1986; 152: 81-84.
21. Harrison CA, Rogers DW, Rosen M. Blood contamination of anaesthetic and related staff. Anaesthesia 1990; 45: 831-833.
22. O'Donnell NG, Asbury AJ. The occupational hazard of human immunodeficiency virus and hepatitis B virus infection. I. Perceived risks and preventive measures adopted by anaesthetists: a postal survey. Anaesthesia 1992; 47: 923-928.
23. Nichols RL, Smith JW. Bacterial contamination of an anesthetic agent. New England Journal of Medicine 1995; 333: 184-185.
24. Langevin PB, Gulig PA, Gravenstein N, Langevin SO. A re-evaluation of the growth rate of Staphylococcus aureus in propofol and intralipid: implications on infection. Anesthesia and Analgesia 1995; 80: S263.
25. Downs GJ, Haley PR, Parent JB. Propofol: can a single ampule be used for multiple patients? Anesthesiology 1991; 74: 1156-1157.
26. Farrington M, McGinnes J, Matthews I, Park GR. Do infusions of midazolam and propofol pose an infection risk to critically ill patients? British Journal of Anaesthesia 1994; 72: 415-417.
27. Warwick JP, Blake D, Drawing up propofol. Anaesthesia 1994; 49: 172
28. Diprivan 1%. In: Walker G, ed. ABPI Data Sheet Compendium 1995-96. London: Datapharm Publications Ltd, 1995; 2039-2041.
29. Lilley EMM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia 1996; 51: 815-818.
30. Gehan G, Karoubi P, Quinet F, Leroy A, Rathat C, Pourriat JL. Optimal dose of lignocaine for preventing pain on injection of propofol. British Journal of Anaesthesia 1991; 66: 324-326.
31. Johnson RA, Harper NJ, Chadwick S, Vohra A. Pain on injection of propofol. Methods of alleviation. Anaesthesia 1990; 45: 439-442.
32. King SY, Davis FM, Wells JE, Murchison DJ, Pryor PJ. Lidocaine for the prevention of pain due to injection of propofol. Anesthesia and Analgesia 1992; 74: 246-249.
33. Cameron E, Johnston G, Crofts S, Morton NS.The minimum effective dose of lignocaine to prevent injection pain due to propofol in children. Anaesthesia 1992; 47: 604-606.
34. Weinstein MP, Maderazo E, Tilton R, Maggini G, Quintiliani R. Further observations on the antimicrobial effects of local anesthetic agents. Current Therapeutic Research, Clinical and Experimental 1975; 17: 369-374.
35. Schmidt RM, Rosenkranz HS. Antimicrobial activity of local anesthetics: lidocaine and procaine. Journal of Infectious Diseases 1970; 121: 597-607.
36. Kirk GA, Koontz FP, Chavez AJ. Lidocaine inhibits growth of Staphylococcus aureus in propofol. Anesthesiology 1992; 77; A407.
37. Zaidi S, Healy TE. A comparison of the antibacterial properties of six local analgesic agents. Anaesthesia 1977; 32: 69-70.
38. Crowther J, Hrazdu J, Jolly DT, Galbraith JC, Greacen M, Grace M. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesthesia and Analgesia 1996; 82: 475-478.
39. Reller LB, Stratton CW. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. Journal of Infectious Diseases 1977; 136: 196-204.
40. Pearson RD, Steigbigel RT, Davis HT, Chapman SW. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrobial Agents and Chemotherapy 1980; 18: 699-708.
41. Gould JC. The laboratory control of antibiotic therapy. British Medical Bulletin 1960; 16: 29-34.
42. Morello JA, Mizer HE, Wilson ME, Granato PA. Tools and techniques in microbiology. In: Johnson M, ed. Microbiology in Patient Care. Dubuque, Iowa: Wm. C. Brown Publishers, 1994; 62-84.